Technology
Health
Biotechnology

Trillium Therapeutics

$0.6598
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.0292 (-4.43%) Today
+$0.0298 (4.73%) After Hours

Why Robinhood?

You can buy or sell TRIL and other stocks, options, ETFs, and crypto commission-free!

About

Trillium Therapeutics Inc. Common Shares, also called Trillium Therapeutics, is a clinical stage immuno-oncology company, which engages in the development of therapies for the treatment of cancer. Read More Its pipeline is comprised of TTI-621, TTI-622, and TTI-2341(EGFR Inhibitor). The company was founded on March 31, 2004 and is headquartered in Mississauga, Canada.

Employees
60
Headquarters
Mississauga, Ontario
Founded
2004
Market Cap
16.56M
Price-Earnings Ratio
Dividend Yield
Average Volume
389.34K
High Today
$0.6716
Low Today
$0.625
Open Price
$0.66
Volume
714.78K
52 Week High
$7.00
52 Week Low
$0.5146

Collections

Technology
Health
Biotechnology
Therapy
Medical
Cancer Prevention
2014 IPO
Canada

News

Yahoo FinanceMay 13

Trillium: 1Q Earnings Snapshot

MISSISSAUGA, Ontario (AP) _ Trillium Therapeutics Inc. (TRIL) on Monday reported a loss of $8 million in its first quarter. On a per-share basis, the Mississauga, Ontario-based company said it had a loss of 46 cents. The company's shares closed at 59 cents. A year ago, they were trading at $6.60. _____ This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on TRIL at https://www.zacks.com/ap/TRIL...

257
Associated PressApr 30

Trillium Announces Management and Board Changes and Provides Corporate Update

TORONTO, April 30, 2019 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, announces changes to its executive management team, its board of directors and provides an operational update. Corporate Governance Changes Niclas Stiernholm, Ph.D., has informed the Board of Directors of his resignation as President & Chief Executive Officer of the Company effective Ap...

347

Earnings

-$0.91
-$0.81
-$0.71
-$0.61
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
-$0.91 per share
Actual
-$0.61 per share
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.